Cargando…

Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent

Mostrar otras versiones (1)

More sensitive and specific methods for early detection are imperative to improve survival rates in oral cancer. However, oral cancer detection is still largely based on visual examination and histopathology of biopsy material, offering no molecular selectivity or spatial resolution. Intuitively, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kossatz, Susanne, Weber, Wolfgang, Reiner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582799/ https://www.ncbi.nlm.nih.gov/pubmed/28856922 http://dx.doi.org/10.1177/1536012117723786

Ejemplares similares

Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent
por: Kossatz, Susanne, et al.
Publicado: (2016)

Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma
por: Kossatz, Susanne, et al.
Publicado: (2016)

Radioiodinated PARP1 tracers for glioblastoma imaging
por: Salinas, Beatriz, et al.
Publicado: (2015)

Target engagement imaging of PARP inhibitors in small-cell lung cancer
por: Carney, Brandon, et al.
Publicado: (2018)

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes
por: Ambur Sankaranarayanan, Ramya, et al.
Publicado: (2020)

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy
por: Nguyen, Nghia T., et al.
Publicado: (2022)

Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening
por: Strome, Arianna, et al.
Publicado: (2018)

Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers
por: Kossatz, Susanne, et al.
Publicado: (2020)

PARPi-FL - a Fluorescent PARP1 Inhibitor for Glioblastoma Imaging
por: Irwin, Christopher P., et al.
Publicado: (2014)

Pulmonary and renal protection: targeting PARP to ventilator-induced lung and kidney injury?
por: Matejovic, Martin, et al.
Publicado: (2010)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Impact of oral antidiabetic agents on bone metabolism
por: Paul, Thomas V., et al.
Publicado: (2015)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
por: Bayley, Rachel, et al.
Publicado: (2023)

Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer
por: Smet, Stéphanie, et al.
Publicado: (2020)

Gaming disorder: Its delineation as an important condition for diagnosis, management, and prevention
por: Saunders, John B., et al.
Publicado: (2017)

Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications
por: Joshi, Bishnu P., et al.
Publicado: (2018)

Detecting Demyelination by PET: The Lesion as Imaging Target
por: Brugarolas, Pedro, et al.
Publicado: (2018)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

Odontonutraceuticals: Pleiotropic Phytotherapeutic Agents for Oral Health
por: Varoni, Elena Maria, et al.
Publicado: (2016)

PARP inhibition and immunotherapy: a promising duo in fighting cancer
por: Phillipps, Jordan, et al.
Publicado: (2023)

A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
por: Furuse, Junji
Publicado: (2019)

Fluorescence-guided resection of tumors in mouse models of oral cancer
por: Demétrio de Souza França, Paula, et al.
Publicado: (2020)

In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent
por: Brand, Christian, et al.
Publicado: (2014)

The case for a stratified application of targeted agents against pancreatic cancer
por: Bijlsma, Maarten F.
Publicado: (2021)

Comparison of initial computed tomography-based target delineation and subsequent magnetic resonance imaging-based target delineation for cervical cancer brachytherapy
por: Corriher, Taylor J., et al.
Publicado: (2020)

Delineating the transcriptional atlas for impaired insulin secretion: A window into type 2 diabetes pathophysiology
por: Li, Jian, et al.
Publicado: (2023)

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents
por: Zhou, Dong, et al.
Publicado: (2021)

Effective Utilization of Oral Hypoglycemic Agents to Achieve Individualized HbA1c Targets in Patients with Type 2 Diabetes Mellitus
por: Bannister, Margaret, et al.
Publicado: (2016)

Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic properties
por: Kossatz, Susanne, et al.
Publicado: (2013)

Pharmacokinetic characterization of fluorocoxib D, a cyclooxygenase-2-targeted optical imaging agent for detection of cancer
por: Cekanova, Maria, et al.
Publicado: (2020)

uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection
por: Yang, Lily, et al.
Publicado: (2013)

Optical delineation of human malignant melanoma using second harmonic imaging of collagen
por: Thrasivoulou, C., et al.
Publicado: (2011)

Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer
por: Pallocca, Matteo, et al.
Publicado: (2018)

Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer
por: Davey, Matthew G, et al.
Publicado: (2023)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Deep learning for epileptogenic zone delineation from the invasive EEG: challenges and lookouts
por: Hoogteijling, Sem, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ri1sjvfrobn6b63uv6ub4c4kg0